About The Study: This study evaluated the response to a third and fourth Pfizer-BioNTech COVID-19 vaccine dose among individuals age 60 or older in Israel by evaluating antispike immunoglobulin G antibody titers before and after each dose. This population is at high risk of developing severe SARS-CoV-2 disease and was the first to receive authorization for a third and fourth vaccine dose.
Authors: Noa Eliakim-Raz, M.D., of Beilinson Hospital in Petah Tikva, Israel, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamanetworkopen.2022.23090)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2022.23090?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=072122
About JAMA Network Open: JAMA Network Open is the new online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.
JAMA Network Open